Maurer B J, Metelitsa L S, Seeger R C, Cabot M C, Reynolds C P
B.J. Maurer, L.S. Metelitsa, R.C. Seeger, Division of Hematology-Oncology, Childrens Hospital Los Angeles, California, USA.
J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46. doi: 10.1093/jnci/91.13.1138.
The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) is toxic to myeloid leukemia and cervical carcinoma cell lines, probably in part due to its ability to increase levels of reactive oxygen species (ROS). We have studied the effects of 4-HPR on neuroblastoma cell lines. Since neuroblastomas commonly relapse in bone marrow, a hypoxic tissue compartment, and many chemotherapeutic agents are antagonized by hypoxia, our purpose was to study in these cell lines several factors influencing 4-HPR-induced cytotoxicity, including induced levels of ROS, effects of physiologic hypoxia and antioxidants, levels of ceramide, and the mechanism of cell death.
ROS generation was measured by carboxydichlorofluorescein diacetate fluoresence. Ceramide was quantified by radiolabeling and thin-layer chromatography. Immunoblotting was used to assess p53 protein levels. Apoptosis (programmed cell death) and necrosis were analyzed by nuclear morphology and internucleosomal DNA fragmentation patterns. Cytotoxicity was measured by a fluorescence-based assay employing digital imaging microscopy in the presence or absence of the pancaspase enzyme inhibitor BOC-d-fmk. Statistical tests were two-sided.
RESULTS/CONCLUSIONS: In addition to increasing ROS, 4-HPR (2.5-10 microM) statistically significantly increased the level of intracellular ceramide (up to approximately 10-fold; P<.001) in a dose-dependent manner in two neuroblastoma cell lines, one of which is highly resistant to alkylating agents and to etoposide. Cell death induced by 4-HPR was reduced but not abrogated by hypoxia in the presence or absence of an antioxidant, N-acetyl-L-cysteine. Expression of p53 protein was not affected by 4-HPR. Furthermore, the pan-caspase enzyme inhibitor BOC-d-fmk prevented apoptosis, but not necrosis, and only partially decreased cytotoxicity induced by 4-HPR, indicating that 4-HPR induced both apoptosis and necrosis in neuroblastoma cells.
4-HPR may form the basis for a novel, p53-independent chemotherapy that operates through increased intracellular levels of ceramide and that retains cytotoxicity under reduced oxygen conditions.
合成类视黄醇N-(4-羟基苯基)视黄酰胺(4-HPR或非雷特)对髓样白血病和宫颈癌细胞系有毒性,这可能部分归因于其提高活性氧(ROS)水平的能力。我们研究了4-HPR对神经母细胞瘤细胞系的影响。由于神经母细胞瘤通常在骨髓(一种缺氧的组织区室)中复发,且许多化疗药物会受到缺氧的拮抗,我们的目的是在这些细胞系中研究影响4-HPR诱导细胞毒性的几个因素,包括诱导产生的ROS水平、生理性缺氧和抗氧化剂的作用、神经酰胺水平以及细胞死亡机制。
通过羧基二氯荧光素二乙酸酯荧光法测量ROS生成。通过放射性标记和薄层层析法定量神经酰胺。使用免疫印迹法评估p53蛋白水平。通过核形态和核小体间DNA片段化模式分析凋亡(程序性细胞死亡)和坏死。在存在或不存在泛半胱天冬酶抑制剂BOC-d-fmk的情况下,采用基于荧光的数字成像显微镜测定法测量细胞毒性。统计检验为双侧检验。
结果/结论:除了增加ROS外,4-HPR(2.5 - 10 microM)在两种神经母细胞瘤细胞系中以剂量依赖方式使细胞内神经酰胺水平在统计学上显著升高(高达约10倍;P <.001),其中一种细胞系对烷化剂和依托泊苷具有高度抗性。在存在或不存在抗氧化剂N-乙酰-L-半胱氨酸的情况下,缺氧会降低但不会消除4-HPR诱导的细胞死亡。4-HPR对p53蛋白的表达没有影响。此外,泛半胱天冬酶抑制剂BOC-d-fmk可阻止凋亡,但不能阻止坏死,且仅部分降低4-HPR诱导的细胞毒性,这表明4-HPR在神经母细胞瘤细胞中诱导了凋亡和坏死。
4-HPR可能构成一种新型的、不依赖p53的化疗基础,该化疗通过增加细胞内神经酰胺水平起作用,并且在低氧条件下仍保持细胞毒性。